PROCEPT BioRobotics/$PRCT
Procept BioRobotics falls after reporting Q3 results and issuing FY2026 revenue guidance of $410M–$430M, reflecting cautious growth outlook.
48 minutes agoLightyear AI
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About PROCEPT BioRobotics
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
Ticker
$PRCT
Sector
Primary listing
Employees
756
Headquarters
Website
PRCT Metrics
BasicAdvanced
$1.9B
-
-$1.56
1.04
-
Price and volume
Market cap
$1.9B
Beta
1.04
52-week high
$96.70
52-week low
$32.11
Average daily volume
1.2M
Financial strength
Current ratio
9.212
Quick ratio
7.713
Long term debt to equity
20.039
Total debt to equity
20.572
Interest coverage (TTM)
-23.64%
Profitability
EBITDA (TTM)
-86.032
Gross margin (TTM)
64.19%
Net profit margin (TTM)
-30.60%
Operating margin (TTM)
-33.37%
Revenue per employee (TTM)
$360,000
Management effectiveness
Return on assets (TTM)
-12.93%
Return on equity (TTM)
-26.40%
Valuation
Price to revenue (TTM)
6.885
Price to book
5.04
Price to tangible book (TTM)
5.06
Price to free cash flow (TTM)
-21.206
Free cash flow yield (TTM)
-4.72%
Free cash flow per share (TTM)
-1.651
Growth
Revenue change (TTM)
55.71%
Earnings per share change (TTM)
-24.35%
3-year revenue growth (CAGR)
76.87%
3-year earnings per share growth (CAGR)
-6.69%
What the Analysts think about PRCT
Analyst ratings (Buy, Hold, Sell) for PROCEPT BioRobotics stock.
Bulls say / Bears say
Total revenue reached $79.2 million in Q2 2025, up 48% year-over-year, demonstrating strong global demand and increasing procedural volume (BioSpace).
Gross margin expanded to about 65% in Q2 2025, up from 59% in the previous year, reflecting improved operational efficiency and the ability to command premium pricing (BioSpace).
Cash and restricted cash stood at $305.8 million as of June 30, 2025, ensuring strong liquidity to support continued growth efforts (BioSpace).
PROCEPT BioRobotics expects an Adjusted EBITDA loss of $35 million for full-year 2025, indicating it remains unprofitable and faces a difficult path to breakeven (GlobeNewswire).
Global tariffs are projected to create a $1–2 million headwind to gross margin in 2025, posing a risk to the company's margin improvement goals (BioSpace).
A Spruce Point report questioned the safety profile of Aquablation and cited increases in equipment malfunctions, casting doubt on product reliability and highlighting procedural risks (BioSpace).
Data summarised monthly by Lightyear AI. Last updated on 4 Nov 2025.
PRCT Financial Performance
Revenues and expenses
PRCT Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for PROCEPT BioRobotics stock?
PROCEPT BioRobotics (PRCT) has a market cap of $1.9B as of November 05, 2025.
What is the P/E ratio for PROCEPT BioRobotics stock?
The price to earnings (P/E) ratio for PROCEPT BioRobotics (PRCT) stock is 0 as of November 05, 2025.
Does PROCEPT BioRobotics stock pay dividends?
No, PROCEPT BioRobotics (PRCT) stock does not pay dividends to its shareholders as of November 05, 2025.
When is the next PROCEPT BioRobotics dividend payment date?
PROCEPT BioRobotics (PRCT) stock does not pay dividends to its shareholders.
What is the beta indicator for PROCEPT BioRobotics?
PROCEPT BioRobotics (PRCT) has a beta rating of 1.04. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.